Toronto, Ontario–(Newsfile Corp. – March 4, 2021) – PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“ PharmaDrug” or the “Company“) wholly-owned subsidiary, Sariyo Therapeutics Inc. (“Sairiyo”), a biotechnology company focused on the research and development of Cepharanthine, a repurposed and reformulated naturally-derived compound for the potential treatment of cancer, neurological…


Previous articleMINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
Next articleSilo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis